QU

Quantum Base Holdings PLC

IL

Overview

Corporate Details

ISIN(s):
GB00BTXYPJ53
LEI:
9845002F5A9EY5AM4B40
Country:
United Kingdom
Address:
N/A
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Quantum Base Holdings PLC is a quantum science company specializing in anti-counterfeiting and authentication technology. Its core product, Q-ID®, is a unique and uncopiable 'atomic-level fingerprint' that can be applied to products, packaging, and documents. The technology enables instant verification using any standard smartphone, providing a highly scalable and accessible solution for brand protection, supply chain security, and document verification. The company's solution is designed for low-cost integration with existing printing processes and is deployed through partnerships with global security organizations.

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Quantum Base Holdings PLC. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-07-28 08:00
Board/Management Information
Appointment of Non-Executive Director
English 17.0 KB

Automate Your Workflow. Get a real-time feed of all Quantum Base Holdings PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Quantum Base Holdings PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Cantargia Logo
Develops antibody-based drugs targeting IL1RAP for cancer and inflammatory diseases.
Sweden CANTA
Captor Therapeutics S.A. Logo
Develops TPD drugs for oncology and autoimmune disorders, targeting 'undruggable' proteins.
Poland CTX
Developing engineered cellular medicines for regenerative treatment of heart failure.
United Kingdom N/A
Cellectis Logo
Biopharma using gene-editing to create off-the-shelf CAR T-cell cancer therapies.
France ALCLS
Celyad Oncology SA Logo
Clinical-stage biotech developing allogeneic & autologous CAR T-cell therapies for cancer.
Belgium CYAD
Cereno Scientific AB Logo
Clinical-stage biotech developing treatments for rare cardiovascular & pulmonary diseases.
Sweden CRNO
Ceres Power Holdings PLC Logo
Licensing solid oxide tech (SOFC/SOEC) for clean power and green hydrogen to global partners.
United Kingdom CWR
Cessatech A/S Logo
Develops non-invasive pain relief, like a nasal spray, for children.
Denmark CESSA
CHOSA Oncology AB Logo
Develops diagnostics and drug delivery for personalized cancer therapy.
Sweden CHOSA
Cinclus Pharma Holding AB Logo
Late-stage pharma developing a next-gen P-CAB drug for severe GERD and H. pylori.
Sweden CINPHA